Last updated on April 2019

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Platinum-Sensitive Ovarian Cancer in First Relapse
  • Age: Between 18 - 100 Years
  • Gender: Female

Inclusion Criteria:

  1. Female subjects who are at least 18 years of age at the time of informed consent
  2. CA125 less than or equal to 3 x upper limit of normal (ULN) confirmed within 2 weeks of randomization using a centralized laboratory assay
  3. A histologically confirmed diagnosis of high-grade serous epithelial ovarian cancer including primary peritoneal and fallopian tube malignancies; all other histologies, including mixed histology, are excluded
  4. Have been treated with debulking surgery and a first-line platinum-based chemotherapy regimen
  5. Maintenance therapy during the first platinum-free interval is allowed; however, the last dose must have been at least 21 days prior to Randomization. No cancer vaccine therapy is allowed.
  6. Must have evaluable disease by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan, according to RECIST 1.1 (subjects with measurable disease per RECIST 1.1 or radiographically visible and evaluable disease). Subjects with only ascites or pleural effusion are excluded.
  7. Must have relapsed radiographically between 6 months and 36 months of completion of first-line platinum chemotherapy and should be randomized within 16 weeks of radiographic relapse
  8. Must be a candidate for treatment with either carboplatin plus paclitaxel or carboplatin plus PLD
  9. Have a life expectancy of at least 6 months, as estimated by the investigator
  10. Other significant medical conditions must be well-controlled and stable in the opinion of the investigator for at least 30 days prior to Randomization
  11. Have an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
  12. Subjects being enrolled to receive paclitaxel plus carboplatin treatment must have neuropathic function (sensory and motor less than or equal to Grade 2 according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) v4.03 (2010)
  13. Laboratory results within the 2 weeks prior to Randomization must be as follows:
    • Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L
    • Platelet count greater than or equal to 100 x 10^9/L
    • Hemoglobin greater than or equal to 9 g/dL
    • Creatinine less than 1.5 x ULN (CTCAE Grade 1)
    • Bilirubin less than 1.5 x ULN (CTCAE Grade 1)
    • Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) less than 3 x ULN
    • Alkaline Phosphatase less than 2.5 x ULN (CTCAE Grade 1)
    • Baseline albumin greater than or equal to Lower Limit of Normal
  14. Subjects of childbearing potential must be surgically sterile or consent to use a medically acceptable method of contraception throughout the study period. All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy).If a patient of childbearing potential is neither surgically sterile nor postmenopausal, contraceptive measures must start either prior to or at Screening and continue throughout the entire study period and for 5 months after the last dose of Test Article is administered. Pregnant and/or lactating females are excluded
  15. Subject must provide written informed consent and be willing and able to comply with all aspects of the protocol

Exclusion Criteria:

  1. Known central nervous system (CNS) tumor involvement
  2. Evidence of other active invasive malignancy requiring treatment other than surgery in the past 3 years
  3. Clinically significant heart disease (eg, congestive heart failure of New York Heart Association Class 3 or 4 angina, not well controlled by medication, or myocardial infarction within 6 months)
  4. Electrocardiogram (ECG) demonstrating clinically significant arrhythmias that are not adequately medically managed (Note: subjects with chronic atrial arrhythmia, ie, atrial fibrillation or paroxysmal supraventricular tachycardia [SVT], are eligible)
  5. Active serious systemic disease, including active bacterial or fungal infection
  6. Active viral hepatitis or active human immunodeficiency virus (HIV) infection. Asymptomatic positive serology is not exclusionary.
  7. Other concurrent immunotherapy (eg, immunosuppressants or chronic use of systemic corticosteroids, with the exception that low-dose corticosteroids [50 mg/day prednisone or equivalent corticosteroid] are allowed; these should be discussed with the Medical Monitor)
  8. Known allergic reaction to a prior monoclonal antibody therapy or have any documented Anti-Drug Antibody (ADA) response
  9. Previous treatment with farletuzumab or other folate receptor targeting agents
  10. For subjects being enrolled to receive PLD plus carboplatin, prior treatment with anthracyclines or anthracenodiones
  11. Breast-feeding, pregnant, or likely to become pregnant during the study
  12. Any medical or other condition that, in the opinion of the investigator, would preclude the subject's participation in a clinical study
  13. Patients who have had secondary debulking surgery
  14. Currently enrolled in another clinical study or used any investigational drug or device within 30 days (or 5 x half-life for investigational drugs where the half-life is known) preceding informed consent

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.